Ben‐Quan Shen

3.5k total citations
35 papers, 1.8k citations indexed

About

Ben‐Quan Shen is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ben‐Quan Shen has authored 35 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 18 papers in Molecular Biology and 18 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ben‐Quan Shen's work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Angiogenesis and VEGF in Cancer (7 papers). Ben‐Quan Shen is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Angiogenesis and VEGF in Cancer (7 papers). Ben‐Quan Shen collaborates with scholars based in United States, France and United Kingdom. Ben‐Quan Shen's co-authors include Thomas F. Zioncheck, David Y. Lee, Sandhya Girish, Daniela Bumbaca, Ola M. Saad, Jay Tibbitts, Hans‐Peter Gerber, Napoleone Ferrara, Bruce A. Keyt and Gail D. Lewis Phillips and has published in prestigious journals such as Journal of Biological Chemistry, Journal of the American College of Cardiology and Cancer Research.

In The Last Decade

Ben‐Quan Shen

34 papers receiving 1.7k citations

Peers

Ben‐Quan Shen
Kendall D. Carey United States
Christine Tan United States
Douglas Armellino United States
Christian D. Young United States
Patrick A. Mayes United States
April A. N. Rose Canada
Mohit Trikha United States
Andreas Menrad Germany
Thomas Holbro Switzerland
Ka Yin Kwong United States
Kendall D. Carey United States
Ben‐Quan Shen
Citations per year, relative to Ben‐Quan Shen Ben‐Quan Shen (= 1×) peers Kendall D. Carey

Countries citing papers authored by Ben‐Quan Shen

Since Specialization
Citations

This map shows the geographic impact of Ben‐Quan Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben‐Quan Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben‐Quan Shen more than expected).

Fields of papers citing papers by Ben‐Quan Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben‐Quan Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben‐Quan Shen. The network helps show where Ben‐Quan Shen may publish in the future.

Co-authorship network of co-authors of Ben‐Quan Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Ben‐Quan Shen. A scholar is included among the top collaborators of Ben‐Quan Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben‐Quan Shen. Ben‐Quan Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Hongzhi, Ran Li, Shraddha Sadekar, Amrita V. Kamath, & Ben‐Quan Shen. (2024). A novel approach to quantitate biodistribution and transduction of adeno-associated virus gene therapy using radiolabeled AAV vectors in mice. Molecular Therapy — Methods & Clinical Development. 32(3). 101326–101326. 1 indexed citations
3.
Liao, Michael Z., Dan Lu, Tong Lu, et al.. (2024). Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings. Advanced Drug Delivery Reviews. 207. 115193–115193. 2 indexed citations
4.
Phillips, Gail D. Lewis, Jun Guo, James R. Kiefer, et al.. (2021). Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Breast Cancer Research and Treatment. 191(2). 303–317. 17 indexed citations
5.
LaPointe, Nichole E., Olga Azarenko, Herb P. Miller, et al.. (2021). Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. Toxicology and Applied Pharmacology. 421. 115534–115534. 67 indexed citations
6.
Cai, Hao, Victor Yip, Sylvia Wong, et al.. (2020). Characterization of Tissue Distribution, Catabolism, and Elimination of an Anti–Staphylococcus aureus THIOMAB Antibody-Antibiotic Conjugate in Rats. Drug Metabolism and Disposition. 48(11). 1161–1168. 9 indexed citations
7.
8.
Shemesh, Colby S., Joy Hsu, Iraj Hosseini, et al.. (2020). Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Molecular Therapy. 29(2). 555–570. 188 indexed citations
9.
Shen, Ben‐Quan, Daniela Bumbaca, Ola M. Saad, et al.. (2015). Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. Drug Metabolism Letters. 9(2). 119–131. 17 indexed citations
10.
Chen, Yuan, Divya Samineni, Sophie Mukadam, et al.. (2014). Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates. Clinical Pharmacokinetics. 54(1). 81–93. 32 indexed citations
11.
Kamath, Amrita V., Victor Yip, Priyanka Gupta, et al.. (2014). Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. mAbs. 6(6). 1631–1637. 15 indexed citations
12.
Bender, Brendan C., Douglas D. Leipold, Keyang Xu, et al.. (2014). A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. The AAPS Journal. 16(5). 994–1008. 64 indexed citations
13.
Shen, Ben‐Quan, Daniela Bumbaca, Ola M. Saad, et al.. (2012). Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism. Current Drug Metabolism. 13(7). 901–910. 92 indexed citations
14.
Bumbaca, Daniela, Hong Xiang, C. Andrew Boswell, et al.. (2011). Maximizing tumour exposure to anti‐neuropilin‐1 antibody requires saturation of non‐tumour tissue antigenic sinks in mice. British Journal of Pharmacology. 166(1). 368–377. 33 indexed citations
15.
Bumbaca, Daniela, Anne Wong, Arthur E. Reyes, et al.. (2011). Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. mAbs. 3(4). 376–386. 72 indexed citations
16.
Shen, Ben‐Quan, et al.. (2004). Combination of Avastin and Xeloda synergistically inhibits colorectal tumor growth in a Colo205 tumor xenograft model.. Cancer Research. 64. 508–508. 11 indexed citations
17.
Shen, Ben‐Quan, et al.. (2001). Vascular Endothelial Growth Factor KDR Receptor Signaling Potentiates Tumor Necrosis Factor-induced Tissue Factor Expression in Endothelial Cells. Journal of Biological Chemistry. 276(7). 5281–5286. 38 indexed citations
18.
Keyt, Bruce A., et al.. (1998). Role of the heparin binding domain in the clearance and localization of vascular endothelial growth factor. Journal of the American College of Cardiology. 31. 461–461. 1 indexed citations
19.
Shen, Ben‐Quan, David Y. Lee, Hans‐Peter Gerber, et al.. (1998). Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro. Journal of Biological Chemistry. 273(45). 29979–29985. 189 indexed citations
20.
Shen, Ben‐Quan, J. H. Widdicombe, & Randall J. Mrsny. (1995). Effects of Lovastatin on Trafficking of Cystic Fibrosis Transmembrane Conductance Regulator in Human Tracheal Epithelium. Journal of Biological Chemistry. 270(42). 25102–25106. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kendall D. Carey Breakdown of academic impact, for papers by Christine Tan Breakdown of academic impact, for papers by Douglas Armellino Breakdown of academic impact, for papers by Christian D. Young Breakdown of academic impact, for papers by Patrick A. Mayes Breakdown of academic impact, for papers by April A. N. Rose Breakdown of academic impact, for papers by Mohit Trikha Breakdown of academic impact, for papers by Andreas Menrad Breakdown of academic impact, for papers by Thomas Holbro Breakdown of academic impact, for papers by Ka Yin Kwong
Rankless by CCL
2026